1) BGI SENTIS™ Lung Cancer Panel

BGI’s lung cancer panel covers 11 genes with direct therapeutic implications for 20 targeted drugs, including those recommended in the latest NCCN guidelines. The panel detects all classes of genomic alterations including SNV, CNV, InDels and Fusion using routine FFPE samples, tumor tissue, DNA or peripheral blood.

GENE
Mutation Types
GENE
Mutation Types
AKT1*SNVKRASSNV
ALKFusion, CNV,SNVMAP2K1SNV
BRAFSNVMETIndel, CNV
DDR2*SNVNRASSNV
EGFRSNV, Indel, CNVNTRK1Fusion
ERBB2Indel, CNVPIK3CASNV
FBXW7*SNVPTEN*SNV
FGFR3FusionRETFusion
HRAS*SNVROS1SNV, Fusion
KIT*SNVTP53*SNV
Product Name
Test Content
Sentis Hereditary Cancer Panel (Female)74 Genes 23 Cancer Types
Sentis Hereditary Cancer Panel (Male)79 Genes 22 Cancer Types
Sentis Hereditary Breast and Ovarian Cancer2 Genes/26 Genes
Sentis Hereditary Colorectal Cancer23 Genes
Sentis Hereditary Prostate Cancer23 Genes
Sentis Hereditary Pancreatic Cancer12 Genes

Panels

Sample Requirements

SENTIS™ Lung Cancer Panel

(Tissue, 20 genes)

> 60 mg tissue

or

10 FFPE 10 mm*10 mm (5-10 μm) sections

or

2-3 samplings of biopsy or ≥ 500 ng good quality, tumor DNA

SENTIS™ Non-invasive Lung Cancer Panel

(ctDNA, 13 genes)

≥ 8mL of peripheral blood (separated plasma and formed elements)

or

≥ 8mL of peripheral blood collected in Streck Cell-Free DNA BCT® tube